摘要
帕金森病(PD)是一种慢性神经退行性疾病。目前PD的诊断主要依据临床症状和体征及对抗PD药物的治疗反应,早期诊断的准确度不高,而灵敏度、特异度较高的生物标志物为疾病早期诊断和新药研发提供了途径。本文从PD的病理机制对脑脊液和血液来源的生物标志物研究现状进行总结,多巴胺代谢产物二羟苯乙酸、路易小体内的α-突触核蛋白及其相关蛋白、氧化应激产物8-羟基脱氧鸟苷和抗氧化剂尿酸、炎症免疫反应因子白细胞介素和神经营养因子等候选生物标志物涉及到PD不同发展阶段。为提高PD早期诊断和药物疗效评估的准确度,建议采用组合生物标志物,即不同机制的生化标志物、影像学和临床症状等手段进行综合评价。
Parkinson disease（PD）is a common,progressive and disabling neurodegenerative movement disorder. Diagnosis of PD depends on clinical history and physical examination,but misdiagnosis is common in early stages because of similar symptoms to other movement disorders. which is why biomarkers are urgently needed to accurately diagnose PD,especially in the early stages of PD,and find new drug targets. This review discusses the curient research of the PD candidate biomarkers from cerebrospinal fluid and blood in terms of PD pathogenesis. We have found that dihydroxyphenylacetic acid,alpha- synuclein and its related proteins in Lewy bodies,8- hydroxy deoxyguanosine,uric acid,interleukin and neurotrophic factors are potential biomarkers. They participate in different stages of PD. In order to enhance the accuracy of early diagnosis and efficacy of drugs evaluation,we are to use multiple biomarkers rather than a single biomarker,in combination with different biologic pathways of biomarkers,neuroimaging as well as clinical symptoms.
出处
《中国药理学与毒理学杂志》
CAS
CSCD
北大核心
2016年第12期1254-1263,共10页
Chinese Journal of Pharmacology and Toxicology
基金
国家科技重大专项(2012ZX09301002-004)
新药作用机制研究与药效评价北京市重点实验室资助(BZ0150)~~
关键词
帕金森病
生物标志物
脑脊液
血液
Parkinson disease
biomarker
cerebrospinal fluid
blood
